Beril Erdogdu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beril Erdogdu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Steven L. Salzberg
Center for Computational Biology, Johns Hopkins University , Baltimore, Maryland, USA
4 shared publications - Ales Varabyou
Department of Computer Science, Johns Hopkins University, Baltimore, MD 21218, USA
3 shared publications - Mihaela Pertea
Department of Computer Science, Johns Hopkins University, Baltimore, MD 21218, USA
3 shared publications Mihaela Pertea
Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA
2 shared publicationsAlaina Shumate
Center for Computational Biology, Johns Hopkins University
1 shared publicationAles Varabyou
Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins School of Medicine and Whiting School of Engineering, Baltimore, MD, USA; Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
Isoswitching in human brain development and aging
Learning, reasoning, and working memory functions are attributed to the dorsolateral prefrontal cortex (DLPFC), a brain region that is highly evolved in primates and notably variable among individuals. Environmental and genetic factors likely contribute to this variability, but little is known about how they influence changes within an individual brain across the lifespan as different cognitive tasks and challenges arise. Most genetic studies focus on DNA mutations or changes in overall gene expression levels. However, genes can also alter the form in which they are expressed through alternative splicing. Using RNA-seq data from prenatal and postnatal human DLPFCs, we observed that many genes undergo a dramatic rewiring of their isoform usage around the time of birth. Further, thousands of genes continue to undergo gradual, temporally regulated shifts in their preferred isoforms, a phenomenon we term ‘isoswitching’. We present isoswitching as a major force in brain development and aging, capable of accurately predicting subject age from prenatal stages through adulthood and beyond eighty years of age. This study represents the first human brain age prediction based solely on RNA-seq data, establishing a molecular framework for understanding normative brain development and aging. We also report isoswitching in the brain of a closely related primate, the rhesus macaque.
Open AccessIsoswitching in human brain development and aging
Learning, reasoning, and working memory functions are attributed to the dorsolateral prefrontal cortex (DLPFC), a brain region that is highly evolved in primates and notably variable among individuals. Environmental and genetic factors likely contribute to this variability, but little is known about how they influence changes within an individual brain across the lifespan as different cognitive tasks and challenges arise. Most genetic studies focus on DNA mutations or changes in overall gene expression levels. However, genes can also alter the form in which they are expressed through alternative splicing. Using RNA-seq data from prenatal and postnatal human DLPFCs, we observed that many genes undergo a dramatic rewiring of their isoform usage around the time of birth. Further, thousands of genes continue to undergo gradual, temporally regulated shifts in their preferred isoforms, a phenomenon we term ‘isoswitching’. We present isoswitching as a major force in brain development and aging, capable of accurately predicting subject age from prenatal stages through adulthood and beyond eighty years of age. This study represents the first human brain age prediction based solely on RNA-seq data, establishing a molecular framework for understanding normative brain development and aging. We also report isoswitching in the brain of a closely related primate, the rhesus macaque.
- Open Access
- 19 March 2024
- Published by Elsevier in Cell Reports Methods
- Vol. 4 (3) , 100736
Detecting differential transcript usage in complex diseases with SPIT
- 19 March 2024
- Published by Elsevier in Cell Reports Methods
- Vol. 4 (3) , 100736
Open AccessDetecting differential transcript usage in complex diseases with SPIT
- Open Access
Detecting differential transcript usage in complex diseases with SPIT
Differential transcript usage (DTU) plays a crucial role in determining how gene expression differs among cells, tissues, and different developmental stages, thereby contributing to the complexity and diversity of biological systems. In abnormal cells, it can also lead to deficiencies in protein function, potentially leading to pathogenesis of diseases. Detecting such events for single-gene genetic traits is relatively uncomplicated; however, the heterogeneity of populations with complex diseases presents an intricate challenge due to the presence of diverse causal events and undetermined subtypes. SPIT is the first statistical tool that quantifies the heterogeneity in transcript usage within a population and identifies predominant subgroups along with their distinctive sets of DTU events. We provide comprehensive assessments of SPIT’s methodology in both single-gene and complex traits and report the results of applying SPIT to analyze brain samples from individuals with schizophrenia. Our analysis reveals previously unreported DTU events in six candidate genes.
Open AccessDetecting differential transcript usage in complex diseases with SPIT
Differential transcript usage (DTU) plays a crucial role in determining how gene expression differs among cells, tissues, and different developmental stages, thereby contributing to the complexity and diversity of biological systems. In abnormal cells, it can also lead to deficiencies in protein function, potentially leading to pathogenesis of diseases. Detecting such events for single-gene genetic traits is relatively uncomplicated; however, the heterogeneity of populations with complex diseases presents an intricate challenge due to the presence of diverse causal events and undetermined subtypes. SPIT is the first statistical tool that quantifies the heterogeneity in transcript usage within a population and identifies predominant subgroups along with their distinctive sets of DTU events. We provide comprehensive assessments of SPIT’s methodology in both single-gene and complex traits and report the results of applying SPIT to analyze brain samples from individuals with schizophrenia. Our analysis reveals previously unreported DTU events in six candidate genes.
- Open Access
Investigating Open Reading Frames in Known and Novel Transcripts using ORFanage
ORFanage is a system designed to assign open reading frames (ORFs) to both known and novel gene transcripts while maximizing similarity to annotated proteins. The primary intended use of ORFanage is the identification of ORFs in the assembled results of RNA sequencing (RNA-seq) experiments, a capability that most transcriptome assembly methods do not have. Our experiments demonstrate how ORFanage can be used to find novel protein variants in RNA-seq datasets, and to improve the annotations of ORFs in tens of thousands of transcript models in the RefSeq and GENCODE human annotation databases. Through its implementation of a highly accurate and efficient pseudo-alignment algorithm, ORFanage is substantially faster than other ORF annotation methods, enabling its application to very large datasets. When used to analyze transcriptome assemblies, ORFanage can aid in the separation of signal from transcriptional noise and the identification of likely functional transcript variants, ultimately advancing our understanding of biology and medicine.
Open AccessInvestigating Open Reading Frames in Known and Novel Transcripts using ORFanage
ORFanage is a system designed to assign open reading frames (ORFs) to both known and novel gene transcripts while maximizing similarity to annotated proteins. The primary intended use of ORFanage is the identification of ORFs in the assembled results of RNA sequencing (RNA-seq) experiments, a capability that most transcriptome assembly methods do not have. Our experiments demonstrate how ORFanage can be used to find novel protein variants in RNA-seq datasets, and to improve the annotations of ORFs in tens of thousands of transcript models in the RefSeq and GENCODE human annotation databases. Through its implementation of a highly accurate and efficient pseudo-alignment algorithm, ORFanage is substantially faster than other ORF annotation methods, enabling its application to very large datasets. When used to analyze transcriptome assemblies, ORFanage can aid in the separation of signal from transcriptional noise and the identification of likely functional transcript variants, ultimately advancing our understanding of biology and medicine.
- Open Access
CHESS 3: an improved, comprehensive catalog of human genes and transcripts based on large-scale expression data, phylogenetic analysis, and protein structure
The original CHESS database of human genes was assembled from nearly 10,000 RNA sequencing experiments in 53 human body sites produced by the Genotype-Tissue Expression (GTEx) project, and then augmented with genes from other databases to yield a comprehensive collection of protein-coding and noncoding transcripts. The construction of the new CHESS 3 database employed improved transcript assembly algorithms, a new machine learning classifier, and protein structure predictions to identify genes and transcripts likely to be functional and to eliminate those that appeared more likely to represent noise. The new catalog contains 41,356 genes on the GRCh38 reference human genome, of which 19,839 are protein-coding, and a total of 158,377 transcripts. These include 14,863 novel protein-coding transcripts. The total number of transcripts is substantially smaller than earlier versions due to improved transcriptome assembly methods and to a stricter protocol for filtering out noisy transcripts. Notably, CHESS 3 contains all of the transcripts in the MANE database, and at least one transcript corresponding to the vast majority of protein-coding genes in the RefSeq and GENCODE databases. CHESS 3 has also been mapped onto the complete CHM13 human genome, which gives a more-complete gene count of 43,773 genes and 19,968 protein-coding genes. The CHESS database is available at http://ccb.jhu.edu/chess .
Open AccessCHESS 3: an improved, comprehensive catalog of human genes and transcripts based on large-scale expression data, phylogenetic analysis, and protein structure
The original CHESS database of human genes was assembled from nearly 10,000 RNA sequencing experiments in 53 human body sites produced by the Genotype-Tissue Expression (GTEx) project, and then augmented with genes from other databases to yield a comprehensive collection of protein-coding and noncoding transcripts. The construction of the new CHESS 3 database employed improved transcript assembly algorithms, a new machine learning classifier, and protein structure predictions to identify genes and transcripts likely to be functional and to eliminate those that appeared more likely to represent noise. The new catalog contains 41,356 genes on the GRCh38 reference human genome, of which 19,839 are protein-coding, and a total of 158,377 transcripts. These include 14,863 novel protein-coding transcripts. The total number of transcripts is substantially smaller than earlier versions due to improved transcriptome assembly methods and to a stricter protocol for filtering out noisy transcripts. Notably, CHESS 3 contains all of the transcripts in the MANE database, and at least one transcript corresponding to the vast majority of protein-coding genes in the RefSeq and GENCODE databases. CHESS 3 has also been mapped onto the complete CHM13 human genome, which gives a more-complete gene count of 43,773 genes and 19,968 protein-coding genes. The CHESS database is available at http://ccb.jhu.edu/chess .
- Open Access
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (25) , eabn3471
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas
Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are an unmet clinical need. Here, we took advantage of the known mechanism of action of TMZ to target guanines (G) and investigated G-rich G-quadruplex (G4) and splice site changes that occur upon TMZ resistance. We report that TMZ-resistant GBM has guanine mutations that disrupt the G-rich DNA G4s and splice sites that lead to deregulated alternative splicing. These alterations create vulnerabilities, which are selectively targeted by either the G4-stabilizing drug TMPyP4 or a novel splicing kinase inhibitor of cdc2-like kinase. Last, we show that the G4 and RNA binding protein EWSR1 aggregates in the cytoplasm in TMZ-resistant GBM cells and patient samples. Together, our findings provide insight into targetable vulnerabilities of TMZ-resistant GBM and present cytoplasmic EWSR1 as a putative biomarker.
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (25) , eabn3471
Open AccessTemozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas
Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are an unmet clinical need. Here, we took advantage of the known mechanism of action of TMZ to target guanines (G) and investigated G-rich G-quadruplex (G4) and splice site changes that occur upon TMZ resistance. We report that TMZ-resistant GBM has guanine mutations that disrupt the G-rich DNA G4s and splice sites that lead to deregulated alternative splicing. These alterations create vulnerabilities, which are selectively targeted by either the G4-stabilizing drug TMPyP4 or a novel splicing kinase inhibitor of cdc2-like kinase. Last, we show that the G4 and RNA binding protein EWSR1 aggregates in the cytoplasm in TMZ-resistant GBM cells and patient samples. Together, our findings provide insight into targetable vulnerabilities of TMZ-resistant GBM and present cytoplasmic EWSR1 as a putative biomarker.